Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Ronald Silver Sells 12,048 Shares

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) insider Ronald Silver sold 12,048 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $21,204.48. Following the completion of the transaction, the insider now owns 279,655 shares in the company, valued at $492,192.80. The trade was a 4.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ironwood Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ IRWD opened at $1.94 on Thursday. Ironwood Pharmaceuticals, Inc. has a 1 year low of $1.59 and a 1 year high of $15.70. The stock’s 50-day simple moving average is $3.63 and its 200-day simple moving average is $4.18.

Wall Street Analyst Weigh In

A number of research analysts have commented on IRWD shares. Craig Hallum reduced their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. JMP Securities reduced their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.67.

Institutional Trading of Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of IRWD. Handelsbanken Fonder AB increased its position in shares of Ironwood Pharmaceuticals by 24.2% during the third quarter. Handelsbanken Fonder AB now owns 59,455 shares of the biotechnology company’s stock worth $245,000 after acquiring an additional 11,600 shares during the last quarter. Inspire Investing LLC increased its holdings in Ironwood Pharmaceuticals by 84.8% in the third quarter. Inspire Investing LLC now owns 101,029 shares of the biotechnology company’s stock valued at $416,000 after buying an additional 46,352 shares during the last quarter. Exchange Traded Concepts LLC bought a new stake in Ironwood Pharmaceuticals in the third quarter valued at about $279,000. Wedge Capital Management L L P NC bought a new stake in Ironwood Pharmaceuticals in the third quarter valued at about $1,297,000. Finally, Creative Planning increased its holdings in Ironwood Pharmaceuticals by 12.7% in the third quarter. Creative Planning now owns 42,151 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 4,749 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.